Grant: Fellowship - PA: CIHR/Rx&D - CAMO Research Program
University of Alberta
$27,500.00
Predictive and prognostic impacts of quality of life measurements and biomarker discovery in chemotherapy treated advanced pancreatic cancer patients in Northern Alberta
FY 2012-13
Summary
Pancreas cancer is a very lethal cancer. The symptoms, such as a lack of appetite, weight loss, fatigue and abdominal pain, are very vague. Consequently, approximately 80% of people diagnosed with pancreas cancer have widespread and incurable disease at the time of their diagnosis. Unfortunately, the treatment options for advanced pancreas cancer are limited. Medical research has shown that a chemotherapy drug, named gemcitabine, can be used in this setting, but it only increases patient lifespan by an average of six weeks. However, gemcitabine does improve how patients feel, in terms of their pain, weight, energy and day-to-day functioning. Because the cure rates for advanced pancreas cancer are so low, it is important to be able to provide these patients with symptom relief and a good quality of life.
Medical research has shown that in some very lethal cancers, such as advanced lung cancer, patients who report a better quality of life before and during treatment experience superior response to chemotherapy and these patients survive longer. This research project aims to investigate how quality of life is related to response to chemotherapy and survival in patients with advanced pancreas cancer. We will investigate patients with advanced pancreas cancer treated at the Cross Cancer Institute in Edmonton, Alberta. In particular, we will collect information on these patients' symptoms, quality of life, treatment, response to therapy and survival. We will also collect samples of patients' tumours to look at various markers that may help predict patient prognosis and response to therapy.
New and improved treatment options are desperately needed for patients with advanced pancreas cancer. This study will allow us to investigate the impact of quality of life on response to therapy and survival and may allow us to personalize therapy and improve care for patients with advanced pancreas cancer.
Department
Program
Fellowship - PA: CIHR/Rx&D - CAMO Research Program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
272936
Name
Kim Christina
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Medical Oncologists (Ottawa)
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Predictive and prognostic impacts of quality of life measurements and biomarker discovery in chemotherapy treated advanced pancreatic cancer patients in Northern Alberta
Programtype2
Fellowship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,500
Cihrequipment2
$0
Programname2
Fellowship - PA: CIHR/Rx&D - CAMO Research Program
Keyworddelim
Biomarkers; Clinical Epidemiology; Database; Pancreas Cancer; Quality Of Life; Survival
Abstract
Pancreas cancer is a very lethal cancer. The symptoms, such as a lack of appetite, weight loss, fatigue and abdominal pain, are very vague. Consequently, approximately 80% of people diagnosed with pancreas cancer have widespread and incurable disease at the time of their diagnosis. Unfortunately, the treatment options for advanced pancreas cancer are limited. Medical research has shown that a chemotherapy drug, named gemcitabine, can be used in this setting, but it only increases patient lifespan by an average of six weeks. However, gemcitabine does improve how patients feel, in terms of their pain, weight, energy and day-to-day functioning. Because the cure rates for advanced pancreas cancer are so low, it is important to be able to provide these patients with symptom relief and a good quality of life.
Medical research has shown that in some very lethal cancers, such as advanced lung cancer, patients who report a better quality of life before and during treatment experience superior response to chemotherapy and these patients survive longer. This research project aims to investigate how quality of life is related to response to chemotherapy and survival in patients with advanced pancreas cancer. We will investigate patients with advanced pancreas cancer treated at the Cross Cancer Institute in Edmonton, Alberta. In particular, we will collect information on these patients' symptoms, quality of life, treatment, response to therapy and survival. We will also collect samples of patients' tumours to look at various markers that may help predict patient prognosis and response to therapy.
New and improved treatment options are desperately needed for patients with advanced pancreas cancer. This study will allow us to investigate the impact of quality of life on response to therapy and survival and may allow us to personalize therapy and improve care for patients with advanced pancreas cancer.
Competitiondate
201210
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kim, Christina
Approvedterm
1 an 0 mois
Cihrcontribution2
Patient Oriented Research~ $27,500~ $0~